IQV

IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions

Retrieved on: 
Tuesday, June 7, 2022
Research, Technology, Clinical Trials, Software, Biotechnology, Pharmaceutical, Health, Data Management, Science, Other Science, Leadership, Privacy, Notre Dame, Computer science, Doctor of Philosophy, Chapel Hill, Real, Public health, Engineering, University, Government, Health, Suretrack Contracts Services, Patient, Technology, Infection, NYSE, COVID-19, Diagnosis, RWS, Industry, IQV, Christina, University of North Carolina at Charlotte, Medical device, Management, Science, IQVIA, Epidemiology

IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the companys Real World Solutions (RWS) business, effective July 7, 2022.

Key Points: 
  • IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the companys Real World Solutions (RWS) business, effective July 7, 2022.
  • Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA.
  • Dr. Mack also serves on the advisory board of the Carolina Health Informatics Program, the ISPE Real World Evidence task force, and co-chairs the Medical Device Epidemiology Network Scientific Oversight Committee.
  • IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.

Global Oncology R&D Surges While Cancer Care Disruptions Ease, Says IQVIA Institute for Human Data Science

Retrieved on: 
Wednesday, June 1, 2022
Data Management, Biotechnology, Technology, Other Health, Health, Pharmaceutical, Oncology, Other Science, Medical Devices, Infectious Diseases, Science, Privacy, Research, Patent, CAR, Cancer, Data science, Composite, Government, Vaccine, Growth, Â, Patient, Technology, Health, NYSE, COVID-19, Oncology, Lung cancer, Diagnosis, Industry, IQV, Institute, Neoplasm, Medical imaging, Pharmaceutical industry, IQVIA

Also, a record 30 novel active substances launched globally last year, according to a new report from the IQVIA Institute for Human Data Science on Global Oncology Trends 2022.

Key Points: 
  • Also, a record 30 novel active substances launched globally last year, according to a new report from the IQVIA Institute for Human Data Science on Global Oncology Trends 2022.
  • Global oncology is a bifurcated tale of two very different worlds, said Murray Aitken, executive director of the IQVIA Institute.
  • On the other hand, the global oncology community and patients continue to struggle with the impact from delays in screenings, diagnoses and cancer care.
  • The IQVIA Institute for Human Data Science contributes to the advancement of human health globally through timely research, insightful analysis and scientific expertise applied to granular non-identified patient-level data.

IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022

Retrieved on: 
Wednesday, May 25, 2022
Research, Technology, Clinical Trials, Software, Biotechnology, Pharmaceutical, Health, Data Management, Science, Other Science, Patient, Industry, Diversified Specialty Institute Holdings, Inc., Conference, Government, Technology, Privacy, NYSE, IQV, Webcast, IQVIA

IQVIA Holdings Inc. (IQVIA) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Jefferies Healthcare Conference in New York City on Friday, June 10, 2022 at 11:30 a.m.

Key Points: 
  • IQVIA Holdings Inc. (IQVIA) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Jefferies Healthcare Conference in New York City on Friday, June 10, 2022 at 11:30 a.m.
  • A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.
  • IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise.

Spending on U.S. Medicines Rose 12% in 2021 Due to COVID-19 Vaccines and Therapies, Says IQVIA Institute for Human Data Science

Retrieved on: 
Thursday, April 21, 2022
Research, General Health, Pharmaceutical, Oncology, Data Management, Medical Devices, Technology, Infectious Diseases, Science, Biotechnology, Other Science, Health, Data science, OOP, Medicine, Population, COVID-19, IQV, Research, Autoimmunity, Organization, Patient, Health care, Growth, Privacy, Technology, Vaccine, Health, NYSE, COVID-19 vaccine, Industry, Institute, Therapy, Government, Pharmaceutical industry, Health insurance, IQVIA

Medicines Trends 2022 Report, released today by the IQVIA Institute for Human Data Science.

Key Points: 
  • Medicines Trends 2022 Report, released today by the IQVIA Institute for Human Data Science.
  • The rise in U.S. medicine spending was largely driven by the increased availability of pandemic vaccines, boosters, and treatments.
  • The IQVIA Institute for Human Data Science contributes to the advancement of human health globally through timely research, insightful analysis and scientific expertise applied to granular non-identified patient-level data.
  • IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise.

IQVIA to Announce First-Quarter 2022 Results on April 27, 2022

Retrieved on: 
Tuesday, April 12, 2022
Data Management, Health, Technology, Research, Science, Biotechnology, NYSE, ID, Privacy, Technology, Diversified Specialty Institute Holdings, Inc., Industry, Patient, Webcast, Government, IQV, IQVIA

IQVIA Holdings Inc. (IQVIA) (NYSE:IQV) will announce its first-quarter 2022 financial results before the market opens on Wednesday, April 27, 2022.

Key Points: 
  • IQVIA Holdings Inc. (IQVIA) (NYSE:IQV) will announce its first-quarter 2022 financial results before the market opens on Wednesday, April 27, 2022.
  • The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date.
  • The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com .

IQVIA Selected to Support EMA’s DARWIN EU® Coordination Centre Initiative

Retrieved on: 
Wednesday, March 30, 2022
Technology, Research, Software, Biotechnology, Networks, Health, General Health, Data Management, Science, Pharmacovigilance, Multinational Medical Coordination Centre/European Medical Command, Real, University, Government, Information management, European Medicines Agency, NYSE, Privacy, Synapse, Data analysis, Industry, Safety, Technology, Knowledge, COVID-19, EMA, IQV, Patient, Pharmaceutical industry, Medical device, IQVIA, Hyves, EU

IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that the European Medicines Agency (EMA) has awarded a contract to Erasmus University Medical Center Rotterdam to provide analytics services to the DARWIN EU Coordination Centre which IQVIA was selected to support.

Key Points: 
  • IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that the European Medicines Agency (EMA) has awarded a contract to Erasmus University Medical Center Rotterdam to provide analytics services to the DARWIN EU Coordination Centre which IQVIA was selected to support.
  • IQVIA will also work alongside the University of Oxford, Synapse, The Hyve, and Odysseus Data Services.
  • The Coordination Centre for the Data Analysis and Real World Interrogation Network, or DARWIN EU, will develop and manage a network of real-world healthcare data sources across the EU to conduct scientific studies requested by medicines regulators and eventually as requested by other stakeholders.
  • The centre will accelerate access to high-quality real-world evidence for the use, safety and effectiveness of drugs across the EU in support of the EMAs regulatory decision-making.

IQVIA Launches OCE+ To Deliver Enhanced AI-Driven Customer Engagement

Retrieved on: 
Tuesday, March 15, 2022
Technology, Research, Software, Biotechnology, Networks, Health, General Health, Data Management, Science, Intelligence, Technology, Government, Patient, ROI, AI, OCE, IQV, IDC, HIMSS, Privacy, NYSE, Next, Next-best-action marketing, Industry, HCP, Medical device, IQVIA

IQVIA (NYSE:IQV) today announced the launch of OCE+, the first of several new advancements to its leading life science customer engagement platform.

Key Points: 
  • IQVIA (NYSE:IQV) today announced the launch of OCE+, the first of several new advancements to its leading life science customer engagement platform.
  • OCE+ adds IQVIAs Next Best recommendation engine a daily workflow tool providing AI-driven recommendations for engaging healthcare professionals (HCP) to its Orchestrated Customer Engagement (OCE) platform, providing enhanced HCP experiences, improved productivity, and increased ROI.
  • IQVIA is uniquely positioned to bring together data, analytics, technology, and AI/ML capabilities all under one roof, said Sanjay Chikarmane, chief product officer, IQVIA.
  • To learn more about IQVIA OCE+, visit and/or tune into IQVIA Technologies at HIMSS 2022 March 14-18, or click here .

IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)

Retrieved on: 
Monday, March 14, 2022
Research, Technology, Clinical Trials, Software, Biotechnology, Hardware, Health, Data Management, Science, Other Science, CRO, Sustainable Development Solutions Network, Industry, University, Business, Government, IQV, Zenith Contract Services, Information Holdings Inc., Leadership, Privacy, NYSE, MBA, DevOps, Patient, Technology, Organization, R, CEO, University of Chicago Booth School of Business, Management, Pharmaceutical industry, Bayer, IQVIA, Biology

IQVIA Holdings Inc. (IQVIA) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit.

Key Points: 
  • IQVIA Holdings Inc. (IQVIA) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit.
  • Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizations.
  • Panagos currently serves as president, Research & Development Operations where he is responsible for the global delivery of all clinical trials, including traditional full-service trials, decentralized clinical trials and flexible staffing arrangements.
  • IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.

IQVIA CFO to Speak at Barclays Global Healthcare Conference on March 16, 2022

Retrieved on: 
Thursday, March 3, 2022
Software, Research, Other Health, Networks, Pharmaceutical, Data Management, Technology, Medical Devices, Security, Science, Biotechnology, Health, Other Science, Technology, Privacy, Conference, Patient, Government, IQV, Industry, NYSE, Diversified Specialty Institute Holdings, Inc., Webcast, IQVIA

IQVIA Holdings Inc. (IQVIA) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 16, 2022 at 1:35 p.m.

Key Points: 
  • IQVIA Holdings Inc. (IQVIA) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 16, 2022 at 1:35 p.m.
  • A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.
  • IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise.

IQVIA selected to accelerate clinical development of VYVGART™ (efgartigimod alfa fcab) by argenx SE

Retrieved on: 
Tuesday, March 1, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Health, Partnership, Government, Privacy, Industry, NYSE, Adult, IQV, FDA, Patient, Technology, Pharmaceutical industry, IQVIA

While terms of the deal have not been disclosed, the collaboration will support clinical development, regulatory, commercial and real-world evidence strategy to accelerate the development of new indications for VYVGART.

Key Points: 
  • While terms of the deal have not been disclosed, the collaboration will support clinical development, regulatory, commercial and real-world evidence strategy to accelerate the development of new indications for VYVGART.
  • IQVIAs end-to-end support will speed the clinical development and the commercial launch of new indications that drive argenxs success.
  • IQVIA brings together deep scientific expertise with unique technology and analytics to enable life sciences companies such as argenx to accelerate the clinical development and commercialization of innovative products that improve patient lives.
  • IQVIA Connected Intelligence delivers powerful insights with speed and agility enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients.